Baker McKenzie is pleased to launch the fifth in our Biden Supply Chain Policy video series focused on the pharmaceuticals and active pharmaceutical ingredients supply chain, which is another of the critical supply chains that has been a particular focus of the Biden Administration. The Biden Administration has been pursuing policies aimed at increasing resilience in this supply chain by addressing shortages and minimizing disruption through a range of measures, including efforts to on-shore and near-shore production to reduce reliance on foreign countries.
In this video Kerry Contini (Partner, Washington DC), Maurice Bellan (Partner, Washington DC), and Veleka Peeples-Dyer (Partner, Washington DC) discuss some of the key legal and compliance considerations for companies operating in this supply chain, with a specific focus on the impacts of the Biden Administration’s policies on FDA regulations and government procurement.
We invite your to watch the other short videos in these series: key trends (see here), the semiconductor supply chain (see here), the large-capacity batteries supply chain (see here) and the critical minerals and strategic materials supply chain (see here).
We hope that you find this discussion to be helpful and encourage you to reach out to us to discuss what the Biden Administration’s supply chain policies may specifically mean for your business.
Click here to watch Video 5: Biden Supply Chain Policy on Pharmaceuticals and Active Pharmaceutical Ingredients
